Interleukin‐1β triggers muscle‐derived extracellular superoxide dismutase expression and protects muscles from doxorubicin‐induced atrophy

Abstract

AbstractDoxorubicin, a conventional chemotherapeutic agent prescribed for cancer, causes skeletal muscle atrophy and adversely affects mobility and strength. Given that doxorubicin‐induced muscle atrophy is attributable primarily to oxidative stress, its effects could be mitigated by antioxidant‐focused therapies; however, these protective therapeutic targets remain ambiguous. The aim of this study was to demonstrate that doxorubicin triggers severe muscle atrophy via upregulation of oxidative stress (4‐hydroxynonenal and malondialdehyde) and atrogenes (atrogin‐1/MAFbx and muscle RING finger‐1) in association with decreased expression of the antioxidant enzyme extracellular superoxide dismutase (EcSOD), in cultured C2C12 myotubes and mouse skeletal muscle. Supplementation with EcSOD recombinant protein elevated EcSOD levels on the cellular membrane of cultured myotubes, consequently inhibiting doxorubicin‐induced oxidative stress and myotube atrophy. Furthermore, doxorubicin treatment reduced interleukin‐1β (IL‐1β) mRNA expression in cultured myotubes and skeletal muscle, whereas transient IL‐1β treatment increased EcSOD protein expression on the myotube membrane. Notably, transient IL‐1β treatment of cultured myotubes and local administration in mouse skeletal muscle attenuated doxorubicin‐induced muscle atrophy, which was associated with increased EcSOD expression. Collectively, these findings reveal that the regulation of skeletal muscle EcSOD via maintenance of IL‐1β signalling is a potential therapeutic approach to counteract the muscle atrophy mediated by doxorubicin and oxidative stress. imageKey points Doxorubicin, a commonly prescribed chemotherapeutic agent for patients with cancer, induces severe muscle atrophy owing to increased expression of oxidative stress; however, protective therapeutic targets are poorly understood. Doxorubicin induced muscle atrophy owing to increased expression of oxidative stress and atrogenes in association with decreased protein expression of extracellular superoxide dismutase (EcSOD) in cultured C2C12 myotubes and mouse skeletal muscle. Supplementation with EcSOD recombinant protein increased EcSOD levels on the cellular membrane of cultured myotubes, resulting in inhibition of doxorubicin‐induced oxidative stress and myotube atrophy. Doxorubicin treatment decreased interleukin‐1β (IL‐1β) expression in cultured myotubes and skeletal muscle, whereas transient IL‐1β treatment in vivo and in vitro increased EcSOD protein expression and attenuated doxorubicin‐induced muscle atrophy. These findings reveal that regulation of skeletal muscle EcSOD via maintenance of IL‐1β signalling is a possible therapeutic approach for muscle atrophy mediated by doxorubicin and oxidative stress.